RA Capital Management is a Boston-based investment firm that pursues evidence-based investing across public and private healthcare, life sciences, and planetary health sectors. The firm supports the growth of innovative companies from seed to later-stage financings, focusing on drugs, medical devices, diagnostics, biotech services, and research tools. RA Capital combines a data-driven research platform, TechAtlas, with a collaborative investment approach and a healthcare incubator, Raven, to help management teams advance ideas from inception through development and commercialization. It frequently co-invests, takes board seats, and participates in follow-on financings, aiming to back ventures that improve patient outcomes and reduce costs. The firm emphasizes US and European opportunities, maintains a multi-stage investment scope, and is headquartered in Boston.

OrbiMed is a global healthcare investment firm focused on supporting the development of therapies, medical devices, diagnostics, and health IT. Established in 1989, it manages a broad investment platform across venture capital, private equity, and public equity, targeting opportunities from early-stage startups to mature companies. The firm backs companies across biopharmaceuticals, biotechnology, life sciences, and digital health, providing financing and strategic resources to accelerate innovation. With a multinational presence and offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, and beyond, OrbiMed pursues a diversified portfolio of healthcare companies worldwide.

Invus is a global investment firm established in 1985 that partners with owner-led and growth companies to create lasting value. It emphasizes long-term relationships, aligns incentives with management, and provides capital and strategic guidance through a flexible structure that supports a wide range of situations. The firm manages multi-billion-dollar evergreen capital and operates from offices in New York, London, Paris, and Hong Kong.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. It operates a multi-strategy platform spanning venture capital, private equity including buyouts, growth equity, and public equity, and invests across biopharmaceuticals, specialty pharmaceuticals, medical devices, diagnostics, and healthcare services. The firm backs hundreds of companies worldwide, with a focus on the United States and China, and maintains a track record of portfolio exits through initial public offerings and mergers and acquisitions. Its team comprises physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build high-quality healthcare companies and advance patient outcomes. Reported assets under management are approximately six billion dollars.

Samsara BioCapital is a biotechnology-focused venture capital firm based in Palo Alto, California, established in 2016. The firm concentrates on funding and supporting biotechnology companies and transformative therapeutics across the United States, leveraging multidisciplinary expertise and strategic partnerships to accelerate clinical and commercial breakthroughs. As a registered investment adviser, Samsara BioCapital combines scientific insight with strategic resources to help entrepreneurs advance innovative medicines.

The European Innovation Council is a European Commission initiative that supports Europe’s deep-tech innovators, researchers, and startups. It funds breakthrough research and technology transfer projects, and delivers equity-like investments through the EIC Fund, as well as prizes and acceleration services to help teams scale. The council also co-invests with private investors in early-stage ventures and places emphasis on high-impact technologies with ESG relevance. Established in 2018 and headquartered in Brussels, it concentrates on deep-tech sectors including defence and dual-use technologies, while promoting international collaboration and market access for awardees. It aims to strengthen Europe’s innovation ecosystem by sharing data, hosting events, publishing insights, and fostering partnerships that accelerate the journey from lab to market.

Morningside Group is a Boston-area venture capital firm founded in 1986 as a family office for the Chan family. It makes long-term investments in companies applying novel science and technology, with expertise in life sciences, digital health, AI, materials, and technology, and a commitment to ethical business practices. The firm supports education, research, and healthcare through charitable initiatives with partners including Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and MIT Morningside Academy for Design.

New Enterprise Associates is a venture capital firm founded in 1977 and headquartered in Menlo Park, California. It provides funding and hands-on support to technology and healthcare startups across stages, from seed to growth and IPO. The firm partners with founders to address technical challenges, guide product development, and expand markets, offering domain expertise and long-term collaboration. Its investment focus spans software, consumer technology, medical devices, healthcare technology, life sciences, artificial intelligence, and related sectors across the United States, Asia, and other regions. NEA emphasizes enduring relationships and collaborates closely with portfolio companies to build transformational businesses.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on early-stage, technology- and science-driven startups, with a strong emphasis on life sciences, biotechnology, pharmaceuticals, healthcare, and related fields. The firm partners with scientists and entrepreneurs to bring academic innovations to market, offering strategic guidance, a deep network, and hands-on involvement beyond capital. It has funded and helped commercialize technologies developed at universities and national laboratories, and maintains a national and international investing footprint with offices in Chicago and Seattle. ARCH has raised multiple funds totaling over three billion dollars and backed more than 150 companies in the venture rounds, reflecting a track record of catalyzing discoveries and building durable companies in science sectors.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotech, life sciences, human health and planetary health, investing in early-stage and growth-stage companies. It provides capital and strategic guidance to portfolio companies across Europe, North America and beyond, and operates a family of funds totaling several billion euros. The firm backs companies in drug development, biotechnology, medical devices and sustainable technologies, with ESG considerations integrated into its investment approach. Its team spans the Netherlands, Germany and the United States, and the firm has notable investments in Azafaros, VectorY and Genomines.

TCG Crossover is a science-driven healthcare investment firm focused on supporting the development of disruptive medicines. It invests in both private and public companies led by entrepreneurs pursuing better treatment options and maintains a portfolio aimed at advancing innovative pharmaceutical solutions. Based in Palo Alto, California, with investment teams in Palo Alto and New York City, the firm targets investments in the United States and Europe, emphasizing healthcare, digital health, and health technology sectors.

Deep Track Capital is a Greenwich, Connecticut-based venture capital firm focused on the biotechnology and life sciences sectors. It invests in public and pre-IPO biotechnology companies and emphasizes partnering with management teams, offering time, expertise, and a broad network in addition to capital. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other qualified investors, providing strategic guidance and resources to portfolio companies.

Logos Capital is an investment firm based in San Francisco that focuses on biotechnology. Founded in 2019, the company combines data analytics with scientific and clinical expertise to identify transformative therapies and opportunities in healthcare. Its multidisciplinary team spans biotechnology, medicine, and data science, and it uses a proprietary Logos Analytics platform to model clinical data, informing diligence and investment decisions. Logos Capital seeks long-term value by providing capital and strategic guidance to companies advancing innovative therapies, applying rigorous risk management and comprehensive analysis of clinical, regulatory, operational, and commercial factors. The firm evaluates opportunities across private and public biotechnology companies, aiming to generate meaningful returns through disciplined research and evidence-based investing.

Deerfield Management is a New York–based healthcare investment firm focused on advancing health outcomes through investment, research, and philanthropy. It invests across public and private markets in biotechnology, pharmaceuticals, diagnostics, healthcare services, medical devices, and digital health, using flexible funding models and strategic partnerships to support companies at various stages and to foster innovation. The firm operates an internal research and development engine to accelerate discovery and development, and maintains a philanthropic foundation that funds education, healthcare access, and initiatives to improve health outcomes. Through collaboration with strategic partners and a commitment to data-driven insights, Deerfield Management seeks to advance healthcare technology and services while building a broader, sustainable health ecosystem.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and based in San Francisco, with offices in Canada and Europe. It invests across the healthcare spectrum, including life sciences, biotechnology, pharmaceuticals and medical devices, at early and later stages. The firm blends deep scientific and operating expertise with investment experience to support company building, often applying a hands-on approach to advancing discoveries from academic origins toward commercial therapies and devices. Through its practice and partnerships, Versant has backed portfolio companies that have achieved acquisitions or public listings, underscoring its track record of translating scientific advances into market outcomes.

Sofinnova Partners is an independent venture capital firm based in Paris, France, founded in 1972. It concentrates on life sciences investments from seed to later-stage, backing biopharmaceuticals, biotech, medical devices and industrial biotechnology, and related areas such as digital medicine and sustainability. The firm actively partners with entrepreneurs, often taking a lead or cornerstone role and serving on boards to guide portfolio companies from formation through exit. It manages substantial assets dedicated to life science investing and has backed more than 500 companies.

Atlas Venture is a Cambridge, Massachusetts-based biotechnology investment firm that partners with life science entrepreneurs to translate scientific discoveries into medicines. With more than 30 years of experience, the firm focuses on creating and building early-stage biotech companies, providing capital, mentorship, and strategic guidance to advance therapies from concept to clinic. Atlas Venture concentrates on biopharmaceuticals, therapeutics, and related life sciences technologies, seeking to lead and support companies through development milestones and to realize value through IPOs, acquisitions, or partnerships. The firm emphasizes collaboration with founders to build scalable businesses that address unmet medical needs and accelerate medical innovation.

SR One Capital Management is the corporate venture capital arm of GlaxoSmithKline, a transatlantic biotechnology-focused investment firm that backs early- to growth-stage life science companies pursuing innovative science with potential to transform medical care. The firm operates across the United States and Europe, with a dual presence on the West Coast and in London, enabling global sourcing and portfolio support. SR One pursues a back-and-build investment approach, prioritizing teams with strong fundamentals, clear development plans, and novel approaches to disease. It provides strategic resources and operational guidance to portfolio companies to accelerate translation of scientific breakthroughs into medicines. Founded in 1985, SR One has invested hundreds of millions in more than 180 companies worldwide, reflecting its long-standing collaboration with GSK and its emphasis on advancing medicines, diagnostics, and related healthcare technologies.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It focuses on seed through early-stage investments and selected later-stage opportunities in life sciences and information technology across the United States and Europe. In life sciences, it backs clinical-stage pharmaceutical products, biotechnology, biopharmaceuticals, therapeutic drugs and medical technology platforms addressing unmet medical needs, with initial investments typically in the low millions and total commitments in the tens of millions; the firm often requires a board seat when leading or co-leading early rounds. In information technology, it supports product-oriented IT, enterprise software, service-provider software and telecommunications infrastructure across development stages. Sofinnova collaborates with entrepreneurs to secure initial funding, build teams, win customers and navigate acquisitions and IPOs, leveraging domain expertise to help portfolio companies scale globally. It does not invest in healthcare services, diagnostics, nutraceuticals or tool-kit ventures.

Omega Funds operates as a Boston-based venture capital investment firm focused on early-stage life sciences and healthcare opportunities in North America and Western Europe. It backs companies across biotechnology, pharmaceuticals, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and SaaS, and manages multiple venture funds including Omega Fund IV, V, VI, and VII. With offices in Boston and Geneva, Omega Funds collaborates with researchers and entrepreneurs to advance medical innovations and bring new therapies and products to patients, pursuing value through strategic support, potential exits, and long-term partnerships.

SOSV is a global venture capital firm headquartered in Princeton, New Jersey, that backs deep-tech startups across seed to growth stages with emphasis on human and planetary health. It provides founders with labs, offices, expert teams, mentorship, investor networks, and accelerator-style programs to accelerate product development, testing, commercialization, and fundraising. SOSV operates three deep-tech facilities, including SOSV SF & NY (IndieBio) and HAX in Newark, and supports a portfolio of more than 800 companies across 58 countries. The firm has a broad global footprint with offices in San Francisco, New York, Newark, and Princeton, has raised over 7.5 billion for its portfolio, and makes approximately 60 pre-seed investments annually alongside many follow-on rounds. It seeks co-investors and limited partners to join its network, and pursues cross-border opportunities, notably in Asia, to accelerate growth and fundraising for its startups.

HBM Healthcare Investments is a Switzerland-based investment firm focused on globally diversified investments in private and public healthcare companies. Founded in 2001 and headquartered in Zug, it concentrates on sectors including human medicine, biotechnology, medical technology and diagnostics, maintaining a portfolio across private holdings, public equities and funds. The company seeks exposure to healthcare growth drivers such as medical innovation, rising access to care and demographic trends, and operates with a global reach to identify opportunities across mature and emerging companies.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. As a venture capital investor and registered investment adviser, it partners with entrepreneurs developing novel medicines and life-saving therapeutics, supporting discovery and development through long-term collaborations. The firm emphasizes a molecular understanding of biology and chemistry to identify promising opportunities with potential patient impact, investing across early-stage and later-stage biotech companies. It backs innovative ventures addressing unmet medical needs and aims to accelerate translational research to bring transformative therapeutics to patients.

Boxer Capital is a biotechnology investment firm that serves as the corporate venture capital arm of Tavistock Group. Based in the United States, the firm invests in public and private biotechnology and life sciences companies across the drug development lifecycle, from early discovery to commercial stage, with a focus on precision medicine and transformative medical advancements. Boxer Capital combines fundamental research with a multidisciplinary analysis of scientific, clinical, regulatory, and commercial factors to translate innovation into opportunity. It pursues opportunities across the full drug lifecycle and provides financial capital and strategic guidance to portfolio companies. The firm notes partnerships with companies such as Mirati Therapeutics and Pandion Therapeutics as examples of its collaborative approach.

Commodore Capital is a New York City-based venture capital firm focused on biopharmaceuticals. Founded in 2019, it seeks to invest in innovative companies developing new medicines and to support them through the early stages of a major innovation cycle in biopharmaceuticals. The firm emphasizes backing ventures driven by genetic and cellular therapy advances from smaller firms, aiming to help bring treatments to patients worldwide. It operates as a registered investment adviser and acts as a collaborative partner to portfolio companies throughout development and commercialization.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across Europe. Founded in 2009, it operates as a management company that backs companies from early creation to development and expansion, often collaborating with leading academic research institutions and hospitals to translate discoveries into medicines and medical devices. The firm manages funds targeting life sciences, pharmaceuticals, biotechnology, digital health and related technologies, supporting European early-stage and growth-stage ventures through strategic partnerships and long-term value creation.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, including drug discovery and oncology. It backs companies from early discovery through development and commercialization, adopting a long-term, hands-on approach that emphasizes deep scientific principles and mentoring of CEOs. The firm seeks to build scientifically driven teams and companies capable of delivering multiple product opportunities. Through a multi-fund investment model, it supports portfolio ventures across biology, chemistry, and technology to accelerate breakthroughs in therapeutics and address unmet medical needs.

Casdin Capital is a New York-based venture capital firm founded in 2012 by Eli Casdin. The firm focuses on life sciences and healthcare, including biotechnology, oncology, digital health, agtech, and related areas, and invests in private companies across stages from early to late, seeking opportunities that leverage data analysis, genomics, and precision medicine. It emphasizes partnerships with experienced teams and maintains a long-term investment horizon, and applies its data expertise to inform investment decisions while upholding ethical considerations in the industry.

BioVenture is a China-based healthcare investment firm anchored in Suzhou's bioBAY ecosystem, specializing in early- and growth-stage life sciences companies. Since 2013, it has supported more than 200 portfolio companies across new drug discovery, medical devices, diagnostics, precision medicine and medical services, with a network built on BioBAY that enables post-investment value-add and rapid growth. The company is known for a seasoned investment team, strong industry resources, and world-class scientific advisors, and has backed multiple portfolio companies that have progressed to public listings on major markets. BioVenture emphasizes global reach, robust deal flow, and a commitment to helping portfolio companies scale through strategic guidance and operational support.

Mission BioCapital is a life science venture capital firm that provides early-stage capital and hands-on support to founders from concept through clinical development. Its leadership team has a long history of collaboration and a track record of launching dozens of early-stage life science ventures, and the firm is known for its deep technical expertise and active, founder-friendly mentorship. With offices in San Francisco and Cambridge, Massachusetts, Mission BioCapital operates in regions rich in research, discovery, and venture activity. The firm offers programs such as the Platinum Program, which provides up to $500,000 in funding, lab space, mentorship, and access to drug discovery, legal, and financial services. It collaborates with corporate and strategic partners to accelerate development and help translate scientific discoveries into therapies, including relationships with AbbVie and Ono Venture Investment. Founded in 2009, Mission BioCapital focuses on early-stage life sciences and biotechnology companies and emphasizes collaboration, innovation, and support for founders to address unmet medical needs.

Pontifax Venture Capital is a Herzliya, Israel-based healthcare-focused venture capital firm that backs transformative life sciences companies worldwide, including pharmaceuticals, biotechnology, and medical devices. Founded in 2004, the firm provides capital and hands-on guidance across development stages, leveraging its industry network and operating experience to support strategic direction, capital markets access, and M&A activity for portfolio companies. Pontifax seeks to source innovative ideas globally and help build successful life sciences businesses through active partnerships and governance, with a focus on turning breakthrough concepts into clinically and commercially viable products.

MPM BioImpact is a venture capital firm based in Boston that invests in biotechnology, healthcare, and life sciences companies across the entire drug development process, from early research to public markets. With over 30 years of experience, the firm backs private and public companies aiming to translate scientific breakthroughs into life-saving medicines. It emphasizes building and supporting ventures that improve patient outcomes, drawing on a team of industry experts and entrepreneur partners. Its portfolio includes Orna Therapeutics, developing circular RNA medicines, Aktis Oncology, pioneering radio-pharmaceuticals, and Reunion Neuroscience, advancing psychedelic-inspired therapies for mental health. MPM BioImpact has demonstrated a track record of backing companies that produce FDA-approved drugs, engage in M&A activity, and pursue initial public offerings, reflecting a continued commitment to advancing innovative therapies.

Merck & Co. is a global, research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines and vaccines to address unmet medical needs worldwide. The company concentrates on oncology, vaccines, infectious diseases, cardiometabolic and respiratory diseases, immunology, neuroscience, and ophthalmology, leveraging data science and AI to advance its pipeline. Its immuno-oncology platform, led by Keytruda, is a major growth driver, while its vaccines business includes pediatric vaccines and Gardasil for HPV. Merck also pursues patient access through assistance programs and engages in sustainability initiatives such as Merck for Mothers. With a history spanning more than a century, the company maintains a global manufacturing and commercial footprint across pharmaceuticals, vaccines, and animal health, guided by scientific innovation, disciplined R&D, and a commitment to improving health outcomes worldwide.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. It focuses on seed- and early-stage investments in life sciences and healthcare, including biopharmaceuticals, medical technology, and related research instruments, with activities across the United States and an office in Boston. The firm backs companies developing innovative medicines and life science tools, aiming to advance therapies and diagnostic technologies through hands-on partnership with founders.

VenBio is a venture capital firm focused on life sciences investing in U.S. based medical and biotechnology companies across early to late stages. The firm leads investments, builds syndicates, and works closely with portfolio teams to advance therapeutics from discovery through clinical development. Its approach emphasizes strong intellectual property, chemistry, manufacturing, and regulatory readiness, and it actively considers potential acquisition partners from the outset to maximize portfolio value. VenBio supports teams through development milestones, aiming to position companies for licensing or acquisition, and has a track record of backing ventures that have delivered FDA-approved drugs. The firm has offices in San Francisco and Seattle and manages nearly $2 billion in committed capital. The firm seeks to partner with industry leaders to address unmet medical needs and create meaningful patient impact.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on technology and healthcare, investing in seed and early-stage companies as well as growth opportunities, and has backed influential firms such as Apple Computer, Intel, Illumina, Nest, and SlideShare. The firm supports portfolio companies across information technology, life sciences, software, cybersecurity, and emerging technologies, pursuing disruptive innovations and long-term growth through partnerships with entrepreneurs to build enduring companies.

Ally Bridge Group is a global healthcare investment firm established in 2013 with offices in New York and Hong Kong. It pursues venture, growth equity, buyout, and public equity investments across private and public markets in the healthcare and life sciences sectors, with emphasis on breakthrough life science innovation, medical devices, biopharmaceuticals, and diagnostics. The firm deploys capital across the United States, China, and Europe, seeking to support early to development-stage companies and to bridge scientific advances with global markets. Its investment approach combines expertise in healthcare investment banking, biotechnology, and pharmaceutical research with capital markets know-how to generate value through strategic synergies across private and public markets.

Pivotal bioVenture Partners is a San Francisco-based venture capital firm focused on early-stage life sciences and therapeutics companies. Founded in 2016, the firm invests across North America, Europe, and China in biotechnology, therapeutics, medical devices, and related life-science platforms addressing unmet medical needs. Its team combines venture investing with company-building and drug-discovery expertise to support entrepreneurs through early development and clinical milestones. The firm maintains a global footprint with offices in San Francisco, Shanghai, and Hong Kong, underscoring its cross-regional approach to health-care innovation. It has established multiple funds to back portfolio companies across cycles.

Abingworth is an international life sciences investment firm with offices in London, Menlo Park, and Boston. Founded in 1973, it collaborates with life sciences entrepreneurs to translate scientific discoveries into therapies and products, investing across all development stages from early startups to publicly traded companies. The firm supports its portfolio with a dedicated team and has invested in more than 140 life science companies, while facilitating 60 IPOs and 40 mergers and acquisitions.

Medicxi is a life sciences focused investment firm established in 2016 by the former Index Ventures life sciences team. Based in London, it backs biotechnology and pharmaceutical ventures across seed, early, and late stages, with a Europe emphasis and activity in the United States. The firm targets therapeutics and drug development, supporting the progression of programs from discovery through translational development. Drawing on its founders' deep experience in drug discovery and unmet medical needs, Medicxi provides capital plus strategic guidance to help biotech companies reach clinical milestones. It also acts as a bridge to larger pharmaceutical partners, facilitating collaborations and licensing opportunities to accelerate drug development in diverse therapeutic areas, including vaccines and related biotech innovations.

Khosla Ventures is a California-based venture capital firm that invests in technology companies across stages, with a focus on artificial intelligence, healthcare, sustainability, climate tech, digital health, and consumer technology. Based in Menlo Park, the firm seeks startups with innovative technologies or business models and provides strategic guidance to help build lasting companies, offering active support to founders to accelerate growth and scale in both early- and later-stage opportunities.

Aisling Capital is a New York-based investment firm focused on healthcare and life sciences. The firm pursues mid-market and growth-stage opportunities in biopharmaceuticals, biotechnology, and related health technologies across the United States and Western Europe, supporting the development and commercialization of new therapeutics and healthcare products. Drawing on extensive industry experience, Aisling Capital provides strategic capital and guidance to portfolio companies to advance scientific breakthroughs from discovery to market.

Catalio Capital Management is a New York-based investment firm focused on healthcare across private, public, and credit markets, with a particular emphasis on biomedical technology, drugs, AI-enabled technologies, and diagnostics. Founded in 2020, it pursues opportunities across the life sciences spectrum using a multi-asset approach that includes venture capital, private equity, private credit, and public equity, often through venture-backed and structured opportunities as well as co-investments. The firm leverages a network of scientist-entrepreneurs to source deals and provide domain insights on emerging trends in life sciences. As of October 1, 2025, Catalio manages about $2 billion in assets and employs more than 40 professionals and a broad group of venture partners. It aims to build category-defining companies and actively engages in IPOs, M&A transactions, and loan repayments within its investment activity.

Alumni Ventures is a venture capital firm headquartered in Manchester, New Hampshire, that expands access to venture investing for accredited individuals by co-investing with leading venture capital firms and enabling participation through various structures such as funds, syndicates, and investment clubs. It collaborates with top firms including Andreessen Horowitz, Sequoia, and Y Combinator and supports opportunities across pre-seed to growth stages, across multiple sectors and geographies. The firm emphasizes rigorous due diligence, transparency, and diversification, leveraging a broad network of alumni investors and partners to connect founders with strategic capital and resources. With a global footprint and active involvement in the venture ecosystem, Alumni Ventures aims to broaden participation in venture capital while maintaining disciplined, founder-friendly investing.

Lumira Ventures is a North American life sciences-focused venture capital firm with offices in Toronto, Boston, Montreal and Vancouver. It invests in biotechnology, biopharmaceuticals, medical devices, digital health and consumer health companies across Canada and the United States, supporting early to late-stage ventures. The firm partners with management teams to build innovative companies addressing significant unmet medical needs, aiming to maximize technology value through financings and active board participation. It assists portfolio companies in accessing capital, strategic partners and market channels to accelerate development and commercialization. With a portfolio of numerous active investee companies, Lumira Ventures draws on deep sector expertise to help companies advance therapies, diagnostics, devices and digital health solutions.

Longitude Capital is a California-based venture growth investment firm that concentrates on biotechnology, medical technology, and health solutions. Founded in 2006, it has raised over $1.2 billion across multiple funds and supports privately held and publicly traded life science companies. The firm emphasizes a balanced portfolio of clinically de-risked assets across clinical- and commercial-stage programs, pursuing attractive returns within three to five years of investment. It identifies opportunities through a broad network of industry relationships and thematic research into emerging therapeutic areas, and uses a range of investment structures including traditional venture financing, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity-linked instruments. Longitude Capital aims to partner with portfolio companies to help them reach strategic objectives, with operations centered in Menlo Park, California.

Third Rock Ventures is a Boston-based venture capital firm that concentrates on early-stage investments in life sciences and healthcare. It backs biotechnology, pharmaceuticals, medical devices, diagnostics, and related information technology companies with high growth potential, providing substantial initial capital and active support to accelerate development and commercial success. The firm emphasizes strategic collaborations and seeks meaningful involvement in portfolio companies, including potential leadership roles, to advance medicines, therapies, and diagnostics. By positioning its investments within the U.S. life sciences landscape, Third Rock Ventures aims to help startups translate scientific breakthroughs into clinically meaningful products and outcomes.

Ysios Capital is an independent life sciences venture capital firm based in San Sebastián, Spain, with additional offices across Europe and North America. Founded in 2008, it provides private equity financing to early- and mid-stage human healthcare and life science companies developing novel therapeutics, diagnostics, medical devices, and platform technologies. The firm pursues a global investment approach, supporting companies across Europe and North America, and often engages with portfolio companies at strategic milestones, including taking board seats when appropriate. Ysios backs a range of modalities, including pharmaceuticals, biotech products, gene therapy, and regenerative medicine, with a focus on disruptive products and platforms that address high unmet medical needs. The firm aims to advance product development toward clinical and commercialization stages, seeking to improve patient lives through innovations in healthcare and biomedicine.

Longwood Fund is a Boston-based venture capital firm that backs science-driven healthcare and life sciences companies. Founded in 2010, it targets solutions for serious medical problems and often collaborates with technology originating from leading labs such as Harvard and MIT. The firm positions itself as a value-add investor, working closely with portfolio companies to translate research into patient therapies, with partners actively engaging as co-founders or senior executives when appropriate. Its focus spans healthcare, pharmaceuticals, biotechnology, and oncology, aiming to accelerate the journey from lab discovery to clinical impact.

IMM Investment is a Seoul-based asset manager and private equity/venture capital firm that engages in multi-asset investments across venture capital, growth equity, mezzanine, and infrastructure. The firm targets information technology, healthcare/biotech, manufacturing, and related high-growth sectors, and often takes an active management role to support portfolio companies. With offices in Seoul, Tokyo, and Hong Kong, it serves institutional investors and partners with innovative entrepreneurs through a diversified platform and cross-border strategies.